Phaseline

Companies › Marea Therapeutics

Marea Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Metabolic and endocrine; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MAR001
APOC3 antisense oligonucleotide
–Phase 2HypertriglyceridemiaNov 2026
MAR002–Phase 2AcromegalyAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07195175MAR002Phase 1AcromegalyMetabolic and endocrineJul 2026
NCT07199309MAR001Phase 2HypertriglyceridemiaMetabolic and endocrineNov 2026
NCT07641179MAR002Phase 2AcromegalyMetabolic and endocrineAug 2027
NCT07028749MAR001Phase 2HypertriglyceridemiaMetabolic and endocrineNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amorphical ERX Pharmaceuticals Hyundai Pharm Rare Thyroid Therapeutics International River 3 Renal

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.